Pfizer said on Thursday that finance chief Dave Denton will step down and leave the U.S. drugmaker on August 15 to take a ...

The pharma company doesn’t have any obesity drugs on the market. Here’s how it plans to change that, and become an industry leader.

Pfizer Inc. raised its 2025 profit forecast for the second time this year, as ongoing cost cuts helped make up for slow sales growth that’s driving its battle for the obesity startup Metsera Inc. The ...

Dec 10 (Reuters) - Pfizer will ‌cut over 200 jobs ‌in Switzerland as part of its multi-year cost reduction program, Bloomberg News reported on ‍Wednesday, citing people familiar with the matter. The ...

Pfizer Inc. is looking to sell its remaining stake in Covid-19 vaccine partner BioNTech SE, a remnant from one of the pandemic’s most lucrative collaborations. The US drugmaker is offering about 4.55 ...

--Pfizer is trying to sell its stake in BioNTech SE, Bloomberg reported, citing people familiar with the matter. --Pfizer is offering 4.55 million American depositary receipts for $108 to $111.70 a ...

FILE PHOTO: A view shows a Novo Nordisk sign outside their office in Bagsvaerd, on the outskirts of Copenhagen, Denmark, July 14, 2025. REUTERS/Tom Little/File Photo (Reuters) -Danish drugmaker Novo ...

Pfizer Inc. Chief Executive Albert Bourla had long searched for an obesity drug to make up for dwindling sales of the pharma company’s aging blockbusters. Late Friday, after a dramatic bidding war, he ...

Connecticut-based Pfizer Inc. said Thursday that it has completed the successful acquisition of Metsera, Inc., which is “a clinical-stage biopharmaceutical company accelerating the next generation of ...